4-(aminomethyl)Cyclohexanecarboxamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-(aminomethyl)Cyclohexanecarboxamide
• 英文别名: 4-(aminomethyl)cyclohexane-1-carboxamide
• 化学式: C₈H₁₆N₂O
• 分子量: 156.23
• InChiKey: RSILLSRLAWUTAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  69.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(aminomethyl)Cyclohexanecarboxamide 生成 4-(Aminomethyl)cyclohexane-1-carboxamide hydrochloride
  参考文献：
  名称：

  OTSUBO, KADZUMASA;YAMANEH, XIROYUKI

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氰基苯甲酰胺 生成 4-(aminomethyl)Cyclohexanecarboxamide
  参考文献：
  名称：

  SUYAMA, SUKEHISI;VADA, TEHTSUO;KONDO, NOBUYUKI;ONO, XIROMOTO

  摘要：

  DOI：

文献信息

• [EN] INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS INDAZOLE COMME ANTAGONISTES DES RÉCEPTEURS CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009134666A1

  公开（公告）日：2009-11-05

  Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  揭示了吲唑烯化合物，其作为CCR1活性拮抗剂是有用的，因此可用于治疗通过CCR1活性介导或维持的多种疾病和疾病，包括自身免疫疾病，如类风湿性关节炎和多发性硬化症。还披露了包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
  申请人：Gerald P.G. Christophe

  公开号：US20060014242A1

  公开（公告）日：2006-01-19

  This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds are selective agonists or antagonists or the Y5 receptor. One such compound has the structure: In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA a normal or a mutant Y5 receptor.

  本发明提供了修改进食行为的方法，包括增加或减少食物摄入量，例如与治疗肥胖症、暴食症或厌食症有关。这些方法涉及到给予选择性Y5受体的激动剂或拮抗剂化合物。其中一种化合物具有以下结构：此外，本发明提供了编码Y5受体的分离核酸分子、分离的Y5受体蛋白、包含编码Y5受体的分离核酸分子的载体、含有这样的载体的细胞、针对Y5受体的抗体、用于检测编码Y5受体的核酸探针、与编码Y5受体的任何独特序列互补的反义寡核苷酸，以及表达正常或突变Y5受体的非人类转基因动物。
• 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer
  申请人：Bailey Peter John

  公开号：US20080058332A1

  公开（公告）日：2008-03-06

  The invention concerns pyrimidine derivatives of Formula (I) wherein each of p, R 1 , R 2 , q, R 3 , r, R 4 , X 1 and Q 1 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the production of an anti-proliferative effect in a warm-blooded animal such as man.

  本发明涉及式(I)的嘧啶衍生物，其中p、R1、R2、q、R3、r、R4、X1和Q1中的每一个具有描述中定义的任何含义；制备它们的过程，含有它们的制药组合物以及它们在制造用于在诸如人类等恒温动物中产生抗增殖效应的药物的制剂中的使用。
• FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS
  申请人：Laing Victoria Elizabeth

  公开号：US20090264411A1

  公开（公告）日：2009-10-22

  A series of 4,5,6,7-tetrahydrothieno[2,3-c]azepin-8-one derivatives, and analogues thereof, which are substituted in the 2-position by a substituted anilino moiety, being selective inhibitors of human MEK (MAPKK) enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.

  一系列4,5,6,7-四氢噻吩[2,3-c]唑啉-8-酮衍生物及其类似物，在2位被取代的苯胺基团取代下，是选择性抑制人类MEK（MAPKK）酶的，因此在医学上具有益处，例如在治疗炎症、自身免疫、心血管、增生（包括肿瘤）和疼痛性疾病方面。
• Aza-quinolinol phosphonate integrase inhibitor compounds
  申请人：Jin Haolun

  公开号：US20070185007A1

  公开（公告）日：2007-08-09

  Aza-quinolinol phosphonate compounds and methods for inhibition of HIV-integrase are disclosed. Formula (I). Ar is aryl or heteroaryl connecting R 6 to L. L is a bond or a linker connecting a ring atom of Ar to N. The ring atoms, X 1 -X 5 may be N, substituted nitrogen, or substituted carbon, and form rings. The compounds include at least one phosphonate group covalently attached at any site.

  本发明公开了一种Aza-quinolinol磷酸酯化合物及其抑制HIV整合酶的方法。 其中公式（I）中，Ar是芳基或杂芳基，连接R6到L。 L是连接Ar的环原子到N的键或连接剂。 环原子X1-X5可以是N，取代氮或取代碳，并形成环。 该化合物在任何位置上至少包括一个共价连接的磷酸酯基团。